Generate:Biomedicines Expands C-suite with Chief Corporate Affairs Officer and Chief Technical Operations Officer
April 30 2024 - 6:00AM
Business Wire
Generate:Biomedicines today announces two key appointments,
welcoming Kimberly (Kym) White as the new Chief Corporate Affairs
Officer and announcing the promotion of Lisa Wyman to Chief
Technical Operations Officer. These appointments not only enhance
the company’s leadership team, but also reflect its commitment to
gender diversity, with over half of the leadership team represented
by women. White's arrival and Wyman's promotion are instrumental as
the company pushes the boundaries of biotechnology, aiming to
transform the landscape of drug discovery and development.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240430610929/en/
Kym White (Photo: Business Wire)
Kym White joins the company with a wealth of experience in the
biotech and pharmaceutical industries, having held significant
roles where she shaped corporate affairs, public policy, and
stakeholder engagement strategies. Her deep understanding of the
critical role AI can play in advancing human health positions her
perfectly to elevate the company's presence in the biotech
industry. As Chief Corporate Affairs Officer, her expertise in
healthcare communications will be pivotal in articulating the
company's mission and in driving forward initiatives that showcase
the innovative work being done in the field of generative
biology.
Lisa Wyman, previously the Senior Vice President of Technical
Operations, has been promoted to Chief Technical Operations
Officer, with an expanded role that now includes leading the
company's Digital organization. This strategic enhancement of her
duties showcases the company's dedication to integrating its
operational excellence with digital capabilities, reinforcing the
symbiotic relationship between its pioneering work in generative
biology and the latest in digital technologies. Wyman's
distinguished track record in optimizing technical operations,
coupled with her visionary leadership in embracing digital
transformation, positions her at the forefront of our mission to
revolutionize medicine development.
“Kym brings a profound understanding of AI’s transformative
power in biotech, paired with her expertise in corporate affairs,
positioning us to amplify our influence and drive meaningful
progress in the industry," said Mike Nally, CEO of
Generate:Biomedicines and CEO-Partner, Flagship Pioneering. "Kym’s
appointment, alongside Lisa’s expanded position, underscores our
commitment to leadership diversity, innovation, and operational
excellence. Together, they will propel us toward our mission to
program biology to transform how medicines are created, developed,
and accessed.”
About Generate:Biomedicines Generate:Biomedicines is the
first drug generation company pioneering a machine learning-powered
generative biology platform with the ability to create new drugs on
demand across a wide range of biologic modalities. The Generate
Platform – which is a continuous loop to generate, build, measure,
and learn – can drastically increase the speed at which targets and
therapeutics are identified and validated. This will improve the
specificity of target engagement by generated proteins and reduce
the time and cost of identifying and developing clinical
candidates. Generate:Biomedicines is a clinical stage company that
was founded by Flagship Pioneering after two years of foundational
research in its Labs unit and launched in 2020. Learn more about
Generate:Biomedicines by visiting
www.generatebiomedicines.com or by following the company on
Twitter and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240430610929/en/
Generate Media Contact Megan McLaughlin
pr@generatebiomedicines.com